HIV drug resistance: brief report 2024
This brief report summarizes recent information on HIV drug resistance (HIVDR) in the era of integrase-strand transfer inhibitors (INSTI) for HIV prevention and treatment. In this report, WHO documents
Drugs
-
Trials by violation
MEDICAL research aims at producing technologies for the human good. But in pursuit of this objective, should we allow medical research to violate basic human rights? The violence of a male-dominated
-
THE MONEY MAKERS
• Nicolas Hayek, chairperson of SMH AG, is looking for a partner to introduce the automotive equivalent of the Swatch watch he made famous in the 1980s. Hayek's inexpensive, stylish and
-
Clipped wings
In the first week of December, the Prime Minister's office gave the go-ahead for the establishment of the National Drug Authority (NDA) to oversee the formulation and supply of medicines in the
-
The best of Indian science
In this and the following issue, DOWN TO EARTH presents a review of India's ten best scientific research projects. The selection is based on the opinions of eminent scientists from reputed institutions. Unravelling the mysteries of the cosmos through stat
-
MONEYMAKERS
• Western mining companies are rushing towards a new eldorado: Cuba. This year, Joutel Resources of Canada became the first western firm to sign an exploration agreement with the Cuban mining
-
A ray of hope for leprosy patients
Two groups of Indian scientists have developed anti leprosy vaccines that they claim are also effective in helping victims recover.
-
Speeding up in the fast lane
India's largest particle accelerator installed in Delhi is a boon for scientists studying the behaviour of particles at high speeds.
-
Molecules made to order
Restructuring molecules for specific purposes be it symmetry of design or to develop medicinal drugs has come of age in India.
-
Power for the future
The Institute of Plasma Research in Gujarat is working to make power generation from nuclear fusion a reality.
-
MONEYMAKERS
• WITH WESTERN governments trying to cut health-care costs and consequently, the pharmaceuticals market becoming more competitive, many companies including Glaxo are keen to move into untapped